Amarantus Bioscience (OTCMKTS:AMBS) versus biote (NASDAQ:BTMD) Critical Analysis

biote (NASDAQ:BTMD) and Amarantus Bioscience (OTCMKTS:AMBS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for biote and Amarantus Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	1	2.50
Amarantus Bioscience	0	0	0	0	0.00

biote presently has a consensus target price of $2.75, indicating a potential upside of 20.09%. Given biote’s stronger consensus rating and higher possible upside, equities research analysts clearly believe biote is more favorable than Amarantus Bioscience.

Profitability

This table compares biote and Amarantus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Amarantus Bioscience	N/A	N/A	N/A

Institutional & Insider Ownership

21.7% of biote shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 10.3% of Amarantus Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares biote and Amarantus Bioscience”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22 million	0.45	$27.05 million	$0.44	5.20
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A

biote has higher revenue and earnings than Amarantus Bioscience.

Risk & Volatility

biote has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Amarantus Bioscience has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Summary

biote beats Amarantus Bioscience on 10 of the 11 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.